Daniel Petrylak

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

Howard I. Scher, Susan Halabi, Ian F. Tannock et al. · Journal of Clinical Oncology · 2008 · 2.2K citations · Full text

Medicine, Oncology, Urology +17

Altered Expression of the Retinoblastoma Gene Product: Prognostic Indicator in Bladder Cancer

Carlos Cordon‐Cardo, David D. Wartinger, Daniel Petrylak et al. · JNCI Journal of the National Cancer Institute · 1992 · 344 citations

Medicine, Molecular Biology, Oncology +12

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

Ian F. Tannock, Karim Fizazi, Camilla Thellenberg Karlsson et al. · The Lancet Oncology · 2013 · 287 citations

Medicine, Oncology, Pharmacology +16

Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group

Howard I. Scher, Mario Eisenberger, Anthony V. D’Amico et al. · Journal of Clinical Oncology · 2004 · 201 citations

Medicine, Oncology, Urology +17

Randomized Study of Three Different Doses of Suramin Administered With a Fixed Dosing Schedule in Patients With Advanced Prostate Cancer: Results of Intergroup 0159, Cancer and Leukemia Group B 9480

Eric J. Small, Susan Halabi, Mark J. Ratain et al. · Journal of Clinical Oncology · 2002 · 54 citations

Medicine, Oncology, Pharmacology +11